• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.
【24h】

Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

机译：早期和晚期cinacalcet的成本效益治疗除了标准的照顾在美国二次肾甲状旁腺功能亢进。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: The objective of this research was to estimate lifetime cost-effectiveness of treating patients with cinacalcet early (when parathyroid hormone [PTH] levels are in the range of 300-500 pg/ml) versus delaying treatment with cinacalcet (cinacalcet initiated when PTH levels are > 800 pg/ml) in patients with secondary hyperparathyroidism (SHPT) in the US setting. METHODS: A Markov model was developed to simulate the effects of early versus delayed use of cinacalcet (plus standard of care). Four different PTH ranges ( 800 pg/ml) were used to represent four different health states within the Markov model. Associated with each Markov state (PTH range) were varying risks of major SHPT complications, including cardiovascular disease (CVD), fracture (Fx), and parathyroidectomy (PTx). Baseline cohort characteristics and risks of CVD, Fx, and PTx by PTH category were derived from a large US renal database and published sources. Costs were estimated from the US Renal Data System database and reported in 2006 US Dollars (Dollars ). Clinical and economic outcomes were discounted at 3.0% per annum. RESULTS: Early treatment was projected to improve quality-adjusted life years (QALYs) by 0.337 years compared to delaying treatment. The incremental cost-effectiveness ratio was Dollars 17,275 per QALY gained. CONCLUSIONS: Early treatment with cinacalcet was associated with improvements in QALYs and would represent good value for money compared to delaying treatment with cinacalcet.
机译：目的:本研究的目的是估计寿命成本效益的治疗cinacalcet患者早期(当甲状旁腺激素(甲状旁腺素)水平在300 - 500的范围pg / ml)和延迟cinacalcet治疗(cinacalcet发起当甲状旁腺素水平> 800pg / ml)患者的次要的甲状旁腺功能亢进(船期)在美国设置。开发方法:马尔可夫模型来模拟早期与延迟使用的影响cinacalcet(加上标准的护理)。不同的甲状旁腺素范围(< = 300 pg / ml;pg / ml;代表四个不同健康状态中马尔可夫模型。(甲状旁腺素范围)不同风险的主要船期并发症,包括心血管疾病(CVD)、骨折(外汇)和甲状旁腺切除术(PTx)。心血管疾病、外汇和PTx甲状旁腺素衍生类别从一个美国大型肾数据库和出版来源。数据系统数据库和2006年报告我们美元(美元)。结果在每年3.0%折扣。结果:早期治疗将提高0.337质量调整生命年(提升)年相比,延迟治疗。增量成本效益比是美元17275每QALY上涨。cinacalcet治疗有关改善qaly,将是好物有所值而延误治疗cinacalcet。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号